NetworkNewsBreaks – Genprex, Inc. (NASDAQ: GNPX)
Post# of 231
Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) this morning announced its placement in an editorial published by NetworkNewsWire (“NNW”), a multifaceted financial news and publishing company for private and public entities. The publication, titled “Gene Therapies with Potential to Conquer Tough-to-Tackle Breast Cancers,” may be accessed via the following link: http://nnw.fm/pNKm2. The editorial reads,“‘Disruptive’ isn’t a term that’s often applied to medicine, where the aim is to avoid disrupting the health of the human body. But technology such as Genprex Inc.’s (NASDAQ: GNPX) Oncoprex(TM) immunogene therapy is disruptive precisely because it could improve doctors’ ability to preserve health. It may also change the course of cancer, as new technology often opens up new possibilities.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer